Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232308 | 0.84 | PPARG (0.56) | PPARGPTPN1FFAR1CA2ALDH1A1 | |
| SCHEMBL3922 | 0.83 | PPARA (0.61) | PPARGPTPN1PPARAPPARD | |
| SCHEMBL14379043 | 0.83 | PPARA (0.61) | PPARGPTPN1PPARAPPARD | |
| SCHEMBL20125593 | 0.83 | PPARA (0.61) | PPARGPTPN1PPARAPPARD | |
| SCHEMBL29358494 | 0.83 | PPARA (0.61) | PPARGPTPN1PPARAPPARD | |
| SCHEMBL5707014 | 0.78 | PTPN1 (0.64) | PPARGPTPN1FFAR1CA2ALDH1A1 | |
| SCHEMBL6497355 | 0.78 | PPARG (0.54) | PPARGPTPN1FFAR1CA2ALDH1A1 | |
| SCHEMBL6232906 | 0.77 | PPARA (0.57) | PPARGPTPN1FFAR1CA2ALDH1A1 | |
| SCHEMBL896413 | 0.77 | PPARG (0.52) | PPARGPTPN1FFAR1PPARAPPARD | |
| SCHEMBL7455356 | 0.77 | PTPN1 (0.63) | PPARGPTPN1FFAR1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754032-B2 | Concomitant pharmaceutical agents and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-1894567-B1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-7595333-B2 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-29 | — | — | US | disclosed |
| EP-1931359-A4 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | ELIXIR PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090082256-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1931359-A2 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | Elixir Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1894567-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007033292-A2 | COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION | ELIXIR PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20040106649-A1 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082256-A1 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF | DPP4, DPP7, LIPC | PPARG 12/4885PTPN1 642/4885FFAR1 1582/4885 |
| US-20040106649-A1 | Agent for improving acidosis | GPR119, SLC2A8, SLC2A1 | PPARG 422/4885PTPN1 3972/4885FFAR1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.